Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News RespireRx Pharmaceuticals Inc RSPI

RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders. The Company is focused on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (ADHD... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (GREY:RSPI)

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

GlobeNewswire November 20, 2025

RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement

GlobeNewswire November 19, 2025

RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common Stock

GlobeNewswire November 18, 2025

RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private Placement

GlobeNewswire November 18, 2025

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

GlobeNewswire February 10, 2025

RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury

GlobeNewswire May 29, 2024

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

GlobeNewswire March 20, 2024

RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

GlobeNewswire February 13, 2024

RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors

GlobeNewswire January 22, 2024

Opinion & Analysis (GREY:RSPI)

No current opinion is available.

Bullboard Posts (GREY:RSPI)

Any Updates?

Anyone know anything about this stock?
zerogravity1 - May 18, 2020